May 04, 2018 | The saga of Martin Shkreli and Turing Pharmaceuticals focused a lot of attention on prescription drug prices, but no reversal of the exponential price increases for the lifesaving drug Daraprim resulted. The story offers an object lesson into the interworkings of the pharmaceutical market. Kaiser Health News